

## INTRODUCTION

- Titanium dioxide (titania,  $\text{TiO}_2$ ) is a chemically inert, semiconducting material that also exhibits photocatalytic activity in the presence of light. Čerenkov radiation (CR) is light emission when charged particles travel faster than the phase velocity of light in a dielectric medium.
- Previous studies have shown  $\text{TiO}_2$  nanoparticles predominantly cause adverse effects via induction of oxidative stress resulting in cell damage, genotoxicity, inflammation, immune response etc.
- After being excited by Čerenkov Radiation, titania forms electron-hole pairs and induces the production of reactive oxygen species (ROS).

## AIM

To examine the efficacy of titanium dioxide ( $\text{TiO}_2$ ) nanoparticles incorporated in a smart radiotherapy biomaterial (SRB\_  $\text{TiO}_2$ ) as a novel image contrast agent *in-vivo* and/or therapeutic agent for pancreatic cancer *in vitro* with/without radiotherapy.

## METHOD

- A colony forming assay *in vitro* was conducted using pancreatic cancer cells (KPC / Panc-02) treated with/without  $\text{TiO}_2$  nanoparticles exposed to external beam radiotherapy.
- Smart radiotherapy biomaterials of  $\text{TiO}_2$  (SRB\_  $\text{TiO}_2$ ) (3-5 mm length by 0.85-1.6mm diameter) were developed.
- Release of payload from the SRB\_  $\text{TiO}_2$  was investigated *in-vitro* without radiotherapy.
- Image contrast of SRB\_  $\text{TiO}_2$  was assessed using computed tomography.

### SRB\_ $\text{TiO}_2$



Figure A. Pictorial view of SRB\_  $\text{TiO}_2$  implants

## RESULTS




Figure 1. Panc-02 Cell Viability




Figure 2. KPC Cell Viability




Figure 3. Cumulative Release of Fluorescein dye from SRB\_  $\text{TiO}_2$  over Time



Figure 4. Pictorial view of SRB\_  $\text{TiO}_2$  implants




Figure 5. Computed Tomography images of Mouse with single KPC Tumor on the Left Flank implanted with SRB\_  $\text{TiO}_2$  with no payload

Enhanced cytotoxic effects were observed for both KPC and Panc-02 cells treated with 1uM of  $\text{TiO}_2$  nanoparticles exposed to 2Gy of radiotherapy. Sustained release of payload from SRB\_  $\text{TiO}_2$  was shown for up to 22 days. SRB\_  $\text{TiO}_2$  was clearly visible in CT images like fiducials for image-guided-radiotherapy (IGRT).

Figure 1 & 2 Cell viability results showed greater than 30% decrease in cell colony proliferation exposed to 1uM of  $\text{TiO}_2$  nanoparticle without radiotherapy. With radiotherapy, significant decrease  $p < 0.0001$  in cell viability for cells treated with 4uM at 4Gy of radiotherapy was observed. Figure 5 CT images of the SRB\_  $\text{TiO}_2$  in KPC tumor showed visible image of the implant 22 days post implant.

## CONCLUSIONS

The results demonstrate the potential of next generation SRB\_  $\text{TiO}_2$  optimized for image-guided delivery of immunotherapy drugs in pancreatic tumors.

Radiotherapy beams produce Čerenkov Radiation within tissue, which has been widely studied recently for imaging purposes.

Furthermore, SRB\_  $\text{TiO}_2$  offer a viable pathway to clinical translation as they could simply replace currently used inert radiotherapy (RT) biomaterials (e.g. fiducials, beacons, spacers), at no additional inconvenience to many cancer patients like those with pancreatic, prostate, or lung cancer.

## REFERENCES

- Kumar N et al.  $\text{TiO}_2$  and its composites as promising biomaterials: a review. *Biomaterials* 2018; 31:147–159
- Ashkarran A-A, Hamidinezhad H, Haddad H et al. Double-doped  $\text{TiO}_2$  nanoparticles as an efficient visiblelight-active photocatalyst and antibacterial agent under solar simulated light. *Appl Surf Sci* (2014) 301:338–345
- Nakayama, Masao et al. Titanium peroxide nanoparticles enhanced cytotoxic effects of X-ray irradiation against pancreatic cancer model through reactive oxygen species generation in vitro and in vivo. *Radiat Oncol.* (2016) 11(1):91
- Ouyang, Zi et al. Nanoparticle-aided external beam radiotherapy leveraging the Čerenkov effect. *Physica medica vol.* 32,7 (2016): 944-7.

## ACKNOWLEDGEMENTS

- Brigham and Women's Hospital Biomedical Research Institute
- National Institutes of Health

## CONTACT INFORMATION

Michele Moreau

[Michele\\_Moreau@dfci.harvard.edu](mailto:Michele_Moreau@dfci.harvard.edu)